Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.59 |
| ▸ | CES1 | P23141 | 2/20 | 0.59 |
| ▸ | GSK3B | P49841 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.42 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.41 |
| ▸ | CHRNG | P07510 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29464070 | 1.00 | CES2 (0.59) | CES2CES1GSK3BALDH1A1HIF1A | |
| Hydrochloric Acid SCHEMBL3941502 | 0.96 | CES2 (0.55) | CES2CES1GSK3BALDH1A1HIF1A | |
| SCHEMBL30025571 | 0.84 | GSK3B (0.53) | CES2CES1GSK3BALDH1A1HIF1A | |
| SCHEMBL2630705 | 0.84 | GSK3B (0.53) | CES2CES1GSK3BALDH1A1HIF1A | |
| SCHEMBL5455143 | 0.84 | KDM4E (0.49) | CES2CES1GSK3BALDH1A1HIF1A | |
| SCHEMBL7144096 | 0.84 | GSK3B (0.59) | GSK3BALDH1A1HIF1AMAPK1TRPA1 | |
| SCHEMBL10202980 | 0.84 | CES2 (0.55) | CES2CES1GSK3BALDH1A1DRD2 | |
| SCHEMBL8879619 | 0.82 | GSK3B (0.52) | CES2CES1GSK3BALDH1A1HIF1A | |
| SCHEMBL2686773 | 0.82 | GSK3B (0.47) | CES2CES1GSK3BALDH1A1HIF1A | |
| SCHEMBL6182736 | 0.82 | HDAC1 (0.56) | GSK3BALDH1A1HIF1AMAPK1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113637713-B | Method for preparing chiral 2-chloro-3, 4-difluorophenethyl alcohol | 杭州酶易生物技术有限公司 | 2023-12-22 | — | — | CN | claimed |
| WO-2023223335-A1 | A METHOD FOR PREPARING (1S)-2-CHLORO-1-(3,4-DIFLUOROPHENYL) ETHANOL | AARTI PHARMALABS LIMITED (IN) | 2023-11-23 | — | — | WO | claimed |
| WO-2023142153-A1 | CARBONYL REDUCTASE AND USE THEREOF | 山东寰酶生物制药有限公司 | 2023-08-03 | — | — | WO | claimed |
| CN-115710158-A | Method for preparing ticagrelor intermediate through asymmetric catalysis | 凯特立斯（深圳）科技有限公司 | 2023-02-24 | — | — | CN | claimed |
| CN-113637713-A | Method for preparing chiral 2-chloro-3, 4-difluorophenethyl alcohol | 杭州酶易生物技术有限公司 | 2021-11-12 | — | — | CN | claimed |
| CN-107513035-A | 3,4 difluoro acetophenones substitution viologen compound and its preparation method and application | 上海大学 | 2017-12-26 | — | — | CN | claimed |
| US-5068449-A | FLUORINATED BENZOYL COMPOUNDS | ASAHI GLASS COMPANY, LTD. (JP) | 1991-11-26 | — | — | US | claimed |
| EP-0342849-A2 | Intermediates for preparing 1,4-dihydro-4-oxo-quinoline-3-carboxylic acid esters | PFIZER INC. (US) | 1989-11-23 | — | — | EP | claimed |
| EP-0303291-A2 | Fluorinated benzoyl compounds | ASAHI GLASS COMPANY LTD. (JP) | 1989-02-15 | — | — | EP | claimed |
| JP-1045332-A | — | — | None | — | — | JP | disclosed |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| CN-114317619-B | Method for preparing chiral alcohol by ketone reductase continuous reaction | 山西大学 | 2024-08-27 | — | — | CN | disclosed |
| US-5093515-A | Intermediate for quinolone carboxylic acid bactericide | ASAHI GLASS COMPANY LTD. (JP) | 1992-03-03 | — | — | US | disclosed |
| US-5068449-A | FLUORINATED BENZOYL COMPOUNDS | ASAHI GLASS COMPANY, LTD. (JP) | 1991-11-26 | — | — | US | disclosed |
| US-4994610-A | Process for preparing fluorinated benzoyl compounds | ASAHI GLASS COMPANY, LTD. (JP) | 1991-02-19 | — | — | US | disclosed |
| EP-0411252-A1 | Process for the preparation of fluorobenzoic acids | RIEDEL-DE HAEN AKTIENGESELLSCHAFT (DE) | 1991-02-06 | — | — | EP | disclosed |
| EP-0342849-A2 | Intermediates for preparing 1,4-dihydro-4-oxo-quinoline-3-carboxylic acid esters | PFIZER INC. (US) | 1989-11-23 | — | — | EP | disclosed |
| EP-0303291-A2 | Fluorinated benzoyl compounds | ASAHI GLASS COMPANY LTD. (JP) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | CES2 1096/4885CES1 699/4885GSK3B 1187/4885 |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC3, HDAC1 | CES2 161/4885CES1 201/4885GSK3B 1695/4885 |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | CES2 1096/4885CES1 699/4885GSK3B 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.